Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials

Authors :: Davide Tassinari
Paolo Fabbri
Fabrizio Drudi
M. Nicolini
Maximilian Papi
Eleonora Barzotti
L. Stocchi
Manuela Fantini
Claudio Ridolfi
Lorenzo Gianni
Britt Rudnas
Carlotta Santelmo
Stefania Nicoletti
Emiliano Tamburini
Source :: Journal of Clinical Oncology. 33:e14634-e14634
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e14634 Background: To assess the role of anti-EGFR agents [Cetuximab (C) or Panitumumab(P)] or Bevacizumab (B) in the treatment of RAS wild type metastatic colorectal cancer. Methods: The final res...

Tools